9MW 0211
Alternative Names: 9MW-0211; MW-02Latest Information Update: 24 Aug 2023
At a glance
- Originator Apexigen; Mabwell (Shanghai) Bioscience
- Developer Mabwell (Shanghai) Bioscience; Pyxis Oncology
- Class Eye disorder therapies; Monoclonal antibodies
- Mechanism of Action Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II/III Wet age-related macular degeneration
Most Recent Events
- 23 Aug 2023 Apexigen has been acquired and merged into Pyxis Oncology
- 20 Dec 2021 9MW 0211 is available for licensing as of 20 Dec 2021. https://www.apexigen.com/collaborations/
- 07 May 2021 Phase-II/III clinical trials in Wet age-related macular degeneration (In the elderly, In adults) in China (Intravitreous) (NCT05297292)